American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 791-802 , November 2007

The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis

  • Alexander S. Goldfarb-Rumyantzev, MD, PhD

      Affiliations

    • Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT
    • Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT
    • Corresponding Author InformationAddress correspondence to Alex Goldfarb, MD, PhD, Division of Nephrology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, DA-517, Boston, MA 02215.
    • ,
  • Arsalan N. Habib, MD

      Affiliations

    • Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT
    • ,
  • Bradley C. Baird, MS, MStat

      Affiliations

    • Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT
    • ,
  • Lev L. Barenbaum, PhD

      Affiliations

    • RenalService.com Inc, Salt Lake City, UT.
    • ,
  • Alfred K. Cheung, MD

      Affiliations

    • Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, UT
    • Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT

Received 16 February 2007 ,Accepted 30 July 2007.

References 

  1. Foley RN, Parfrey PS, Sarnak MJ. The clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S112–S119
  2. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559
  3. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ. 2006;332:1115–1124
  4. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160–1164
  5. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582–587
  6. Ness GC, Zhao Z, Lopez D. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation. Arch Biochem Biophys. 1996;325:242–248
  7. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887–1893
  8. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S24–S30
  9. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  10. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  11. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2006;21:2881–2892
  12. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22
  13. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  14. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557–1563
  15. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473–484
  16. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis. 2002;39:1213–1217
  17. Harris KP, Wheeler DC, Chong CC. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int. 2002;61:1469–1474
  18. Lins RL, Matthys KE, Billiouw JM, et al. Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: A placebo-controlled study. Clin Nephrol. 2004;62:287–294
  19. Robson R, Collins J, Johnson R, et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis (The Perfect Study Collaborative Group). J Nephrol. 1997;10:33–40
  20. Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis. 2002;39:283–290
  21. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  22. Fytili CI, Progia EG, Panagoutsos SA, et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail. 2002;24:623–630
  23. Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease. Am J Kidney Dis. 2001;38(suppl 1):S14–S19
  24. Attman PO, Samuelsson OG, Moberly J, et al. Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis. Kidney Int. 1999;55:1536–1542
  25. Horkko S, Huttunen K, Laara E, Kervinen K, Kesaniemi YA. Effects of three treatment modes on plasma lipids and lipoproteins in uraemic patients. Ann Med. 1994;26:271–282
  26. Llopart R, Donate T, Oliva JA, et al. Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant. 1995;10:537–540
  27. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P. Alterations in lipoprotein composition in peritoneal dialysis patients. Perit Dial Int. 2002;22:220–228
  28. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis. Metabolism. 1991;40:1002–1008
  29. Siamopoulos KC, Elisaf MS, Bairaktari HT, Pappas MB, Sferopoulos GD, Nikolakakis NG. Lipid parameters including lipoprotein(a) in patients undergoing CAPD and hemodialysis. Perit Dial Int. 1995;15:342–347
  30. Xue JL, Chen SC, Ebben JP, et al. Peritoneal and hemodialysis: I. Differences in patient characteristics at initiation. Kidney Int. 2002;61:734–740
  31. US Renal Data System. USRDS 2000 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2000;
  32. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33:507–517
  33. Twardowski ZJ, Nolph KD, Prowant BF, Ryan L, Moore HL, Nielsen MP. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138–147
  34. Dupont W. Statistical Modeling for Biomedical Researchers. Cambridge, MA: Cambridge University; 2002;
  35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–383
  36. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant. 2006;21:2881–2892
  37. Greenberg JA. Hypothesis—The J-shaped follow-up relation between mortality risk and disease risk-factor is due to statistical confounding. Med Hypotheses. 2002;59:568–576
  38. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA. 2004;291:451–459
  39. Fox CS, Longenecker JC, Powe NR, et al. Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients. Clin Nephrol. 2004;61:299–307
  40. Kwan BC, Beddhu S, Kronenberg F, Cheung AK: Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nat Clin Pract Nephrol 2:76-77, 200
  41. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;61:297–304
  42. Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction—Are we closing the treatment gap?. Pharmacoepidemiol Drug Saf. 2007;16:773–785
  43. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol. 2007;166:348–354

 Originally published online as doi:10.1053/j.ajkd.2007.07.023 on September 26, 2007.

PII: S0272-6386(07)01130-4

doi: 10.1053/j.ajkd.2007.07.023

American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 791-802 , November 2007

Article Tools

* Image Usage & Resolution